Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.
相关临床试验
14
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2008
进行中（未招募）
1
7.1%
已完成
4
28.6%
招募中
8
57.1%
Unknown
1
7.1%
暂无批准数据
- Immunome director Isaac Barchas sold over $4.39 million in shares in late June and early July 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2026. - The company's lead candidate varegacestat, a gamma secretase inhibitor for desmoid tumors, had its NDA submitted to the FDA in April 2026 with Phase 3 RINGSIDE data selected for ASCO 2026. - Immunome initiated a Phase 1 trial for IM-1617, a potential first-in-class ADC, and continues advancing IM-1021 targeting ROR1 in lymphoma with initial data expected later in 2026. - Wall Street analysts maintain unanimous bullish ratings with a median price target of $36.00, while the company holds $582.7 million in cash expected to fund operations into 2028.
- Immunome is scheduled to announce topline Phase 3 RINGSIDE trial results for varegacestat, an oral gamma secretase inhibitor, in patients with progressive desmoid tumors on December 15, 2025. - The placebo-controlled trial enrolled 156 patients aged 12 and older with progressive desmoid tumors, addressing a significant unmet medical need in rare, locally aggressive soft tissue neoplasms. - Beyond varegacestat, Immunome's pipeline includes multiple first-in-class oncology programs, including ROR1-targeted ADC IM-1021 and FAP-targeted radiotherapy IM-3050. - The company maintains strong financial position with $272.6 million in cash as of September 30, 2025, providing operational runway into 2027.
- IsoBio, Inc. has closed a $5 million Series Seed financing round led by ASP Isotopes Inc. to develop antibody-isotope conjugates (AICs) targeting both validated and novel tumor antigens for cancer treatment. - The strategic partnership with ASP Isotopes and its subsidiary PET Labs aims to address critical isotope supply chain challenges that have historically constrained radiotherapy development and commercialization. - IsoBio is developing radiotherapeutics containing Lutetium-177, Actinium-225, Terbium-161, and other novel radioisotopes using proprietary linker and conjugation technology. - The company is led by radiation oncologist Bruce Turner, M.D., Ph.D., who previously co-led the merger creating Immunome and has extensive experience in targeted oncology therapeutics.
- Iovance Biotherapeutics appointed Corleen Roche as Chief Financial Officer effective August 6, 2025, during the commercial launch of its groundbreaking TIL therapy. - Roche brings 30 years of biotech experience including CFO roles at CG Oncology, Immunome, and Biogen, with expertise in multiple product launches. - The appointment comes as Iovance commercializes Amtagvi, the first FDA-approved T cell therapy for solid tumors, marking a significant milestone in cancer treatment. - Roche will focus on revenue growth and pipeline investments as the company advances its tumor infiltrating lymphocyte platform across multiple solid tumor indications.
- Immunome has dosed the first patient in its Phase 1 trial of IM-1021, a novel ROR1-targeted antibody-drug conjugate designed to treat advanced B-cell lymphomas and solid tumors. - The open-label, multicenter study will evaluate safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of IM-1021, which incorporates Immunome's proprietary TOP1 inhibitor HC74. - This milestone advances Immunome's mission to develop differentiated ADCs for cancer patients with high unmet needs, adding to its growing portfolio of targeted oncology therapeutics.
- Immunome anticipates topline data from the Phase 3 RINGSIDE trial of varegacestat for desmoid tumors in the second half of 2025, marking a key milestone. - The FDA has cleared the IND for IM-1021, a ROR1-targeted antibody-drug conjugate (ADC), paving the way for clinical trials. - Immunome is progressing three novel ADC programs—IM-1617, IM-1340, and IM-1335—for solid tumor indications through preclinical development. - An IND submission for IM-3050, a FAP-targeted radioligand therapy, is expected by the end of the first quarter of 2025, expanding Immunome's pipeline.
